

Synthesis of Necine Bases from Homoproline Derivatives

David W. Knight,^{*,a} Andrew C. Share^a and Peter T. Gallagher^b


^a Chemistry Department, University Park, Nottingham, NG7 2RD, UK

^b Eli Lilly and Co., Lilly Research Centre Ltd., Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK

The α -allyl homoproline ester **8**, obtained by Claisen rearrangement of the allyl ester **7** or direct C-allylation of the homoproline methyl ester **9** has been converted into (–)-trachelanthamidine **4a** and (–)-isoretronecanol **4b** while allylation of the enolate derived from the lactone **13a** followed by related transformations leads stereospecifically to turneforcidine **12**.


Despite the interest in syntheses of necine bases belonging to the pyrrolizidine group of alkaloids,¹ a minority of approaches provide chiral material.² We have found that the related quinolizidine system, e.g. (+)-lupinine **3**, can be obtained from the α -allyl piperidinyllacetate **2** prepared either by direct C-allylation of the piperidinyllacetate **1a** or by an enolate Claisen rearrangement of the corresponding allyl ester **1b**.³ The two approaches are stereochemically complementary; the former route provides largely the *threo* diastereoisomer whereas the Claisen method gives a preponderance of the *erythro* diastereoisomer. In view of this, it appeared that such approaches could be used in the elaboration of related *N*-heterocyclic systems, of which the pyrrolizidines are amongst the most abundant in Nature. Our initial targets were the necine bases (–)-trachelanthamidine **4a** and the epimeric (–)-isoretronecanol **4b**,¹ the key intermediates for which were diastereoisomers of the α -allyl ester **5** which, in turn, should be available either from the allyl ester of an *N*-protected (*S*)-homoproline by an enolate Claisen rearrangement⁴ or by direct allylation.³

Coupling of (*S*)-*N*-BOC-homoproline **6** with allyl alcohol using DCC–DMAP⁵ gave the allyl ester **7** (89%);[†] enolate Claisen rearrangement of which was effected by sequential





Reagents: i, DCC–DMAP, CH₂Cl₂, 20 °C, 16 h; ii, LHMDS, THF, –78 °C, 20 min, TMSCl, 20 min then +60 °C, 4 h; MeOH, H₂O, 20 °C, 0.5 h then CH₂N₂, Et₂O; iii, LHMDS, THF–5 equiv. HMPA –78 °C, 0.25 h, add allyl bromide –78 °C, 0.5 h then warm to +20 °C, 1 h.

[†] Satisfactory analytical and spectroscopic data have been obtained for all new compounds reported.



treatment with LHMDS in THF at -78°C , *O*-silylation (TMSCl) and reflux for 4 h. After hydrolysis (MeOH) and esterification (CH₂N₂), the α -allyl ester **8** was isolated in 78% yield. Alternatively, enolisation of the methyl ester **9** using LHMDS in THF containing HMPA at -78°C followed by addition of allyl bromide also gave the homologated ester **8** (84%). The good yields of the ester **8** from both approaches were offset by an almost total lack of stereoselectivity in either, at best 1.3:1 of difficult to separate diastereoisomers.

However, reduction of the epimeric esters **8** using DIBAL and BF₃·OEt₂^{2d} led to the alcohols (**10a** and **11**) which were readily separable by column chromatography.* The stereochemistries of the two isomers were inferred from comparative spectra data but were only confirmed upon completion of the syntheses. The less polar *erythro* isomer **10a** {[α]_D -25 (CH₂Cl₂)} was protected as the TBDMS ether **10b** (87%) and the alkene function then reductively cleaved by sequential treatment with OsO₄-NaIO₄⁶ and NaBH₄ to give the alcohol **10c** (77%). Subsequent mesylation [MsCl, Et₃N, CH₂Cl₂, 0 $^{\circ}\text{C}$, 1 h] gave the mesylate **10d** (98%). Removal of the BOC function



(20% trifluoroacetic acid in CH₂Cl₂, 0.5 h, 20 $^{\circ}\text{C}$) and basification of the resulting TFA salt (2 mol dm⁻³ NaOH) resulted in cyclisation and deprotection of the primary alcohol group to give, after chromatography [SiO₂; CHCl₃-MeOH-NH₄OH, 5:4:1], (-)-trachelanthamidine **4a** (65%) spectral data for which were identical with those previously recorded as well as [α]_D -14 (c, 0.5; EtOH) {lit.,⁷ [α]_D -13.8 (c, 1.28; EtOH)}. In exactly the same manner, the more polar *threo*

alcohol **11** was converted into (-)-isoretronecanol **4b** which also displayed spectral data identical with those previously reported in addition to [α]_D -77 (c, 0.3; EtOH) {lit.,⁸ [α]_D -78.2 (c, 2.8; EtOH)}. Both samples were single diastereoisomers according to ¹³C spectral data.

This led us to consider better methods for stereochemical control in approaches to more highly oxygenated pyrrolizidines such as turneforicidine **12**.⁹ In this respect, a likely candidate was the lactone **13a**,^{1,10} both enantiomers of which are available.¹¹ Sequential treatment of the racemic *N*-(*Z*)-lactone **13a** with LHMDS in THF at -78°C and allyl bromide gave the α -allyl derivative **13b** (60%) as a single diastereoisomer according to ¹³C NMR data. Subsequent reduction [NaBH₄, EtOH, 20 $^{\circ}\text{C}$, 16 h] gave the diol **14a** (81%) which was protected as its bis-SEM ether **14b** [SEMCl, PrⁱNEt₂, CH₂Cl₂, (78%)]. Reductive cleavage as outlined above then provided the alcohol **14c** (85%). Conversion into the corresponding mesylate **14d** [MsCl, Et₃N; 89%] followed by hydrogenolysis using 10% Pd-C in EtOAc containing Li₂CO₃ [16 h; 20 $^{\circ}\text{C}$] gave the pyrrolizidine **15** (94%). Finally, removal of the two protecting groups (1 mol dm⁻³ TBAF in THF) gave (\pm)-turneforicidine **12**, a viscous oil [lit.,¹² (\pm)-oil], which exhibited spectroscopic and chromatographic properties identical with those reported.^{11,14} The availability of both enantiomers of the starting lactone **13a** suggests that either enantiomer of turneforicidine should be available using this approach.

Acknowledgements

We are grateful to Eli Lilly and Co. and the SERC for financial support under the CASE Scheme and to Dr. Bill Ross for his continued help and encouragement.

References

- For reviews, see D. J. Robins, *Nat. Prod. Rpts.*, 1989, **6**, 577 and previous reports.
- (a) W.-M. Dai, Y. Nagao and E. Fujita, *Heterocycles*, 1990, **30**, 1231; (b) Y. Nagao, W.-M. Dai, M. Ochiai, S. Tsukagoshi and E. Fujita, *J. Org. Chem.*, 1990, **55**, 1148; (c) R. S. Jolly and T. Livinghouse, *J. Am. Chem. Soc.*, 1988, **110**, 7536; (d) T. Moriwake, S. Hamano and S. Saito, *Heterocycles*, 1988, **27**, 1135, and references therein.
- C. Morley, D. W. Knight and A. C. Share, *Tetrahedron Asymmetry*, 1990, **1**, 147.
- R. E. Ireland, R. H. Mueller and A. K. Willard, *J. Am. Chem. Soc.*, 1976, **98**, 2868; C. P. Dell, K. M. Khan and D. W. Knight, *J. Chem. Soc., Chem. Commun.*, 1989, 1812.
- B. Neises and W. Steglich, *Angew. Chem., Int. Ed. Engl.*, 1978, **17**, 522.
- R. Pappo, D. S. Allen Jr., R. U. Lemieux and W. S. Johnson, *J. Org. Chem.*, 1956, **21**, 478.
- Y. Tsuda and L. Marion, *Can. J. Chem.*, 1963, **41**, 1919.
- R. Adams and K. E. Hamlin, *J. Am. Chem. Soc.*, 1942, **64**, 2597.
- A. J. Aasen, C. C. J. Culvenor and L. W. Lewis, *J. Org. Chem.*, 1969, **34**, 4137, and references therein.
- T. A. Geissman and A. C. Waiss, Jr., *J. Org. Chem.*, 1962, **27**, 139.
- H. Rueger and M. Benn, *Heterocycles*, 1982, **19**, 23; J. G. Buchanan, G. Singh and R. H. Wightman, *J. Chem. Soc., Chem. Commun.*, 1984, 1299; K. Shishido, Y. Sukegawa, K. Fukumoto and T. Kametani, *J. Chem. Soc., Perkin Trans. 1*, 1987, 993; N. Ikota and A. Hanaki, *Heterocycles*, 1988, **27**, 2535; J. Copper, P. T. Gallagher and D. W. Knight, *J. Chem. Soc., Chem. Commun.*, 1988, 509; M. Thaning and L.-G. Wistrand, *J. Org. Chem.*, 1990, **55**, 1406.
- T. Ohsawa, M. Ihara, K. Fukumoto and T. Kametani, *J. Org. Chem.*, 1982, **48**, 3644; δ_{C} (CD₃OD) 31.08 (CH₂), 37.03 (CH₂), 40.40 (CH), 53.46 (CH₂), 56.31 (CH₂), 63.70 (CH₂), 70.68 (CH) and 75.66 ppm (CH).

Paper 1/00924I

Received 26th February 1991

Accepted 3rd March 1991

* Silica gel eluted with CH₂Cl₂-EtOAc, 9:1. *R_f* **10a** = 0.53; *R_f* **11** = 0.25.